NO320952B1 - Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl - Google Patents
Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl Download PDFInfo
- Publication number
- NO320952B1 NO320952B1 NO19965523A NO965523A NO320952B1 NO 320952 B1 NO320952 B1 NO 320952B1 NO 19965523 A NO19965523 A NO 19965523A NO 965523 A NO965523 A NO 965523A NO 320952 B1 NO320952 B1 NO 320952B1
- Authority
- NO
- Norway
- Prior art keywords
- virus
- solution
- macromolecule
- protein
- filtration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 46
- 238000011100 viral filtration Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 17
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 55
- 238000001914 filtration Methods 0.000 claims abstract description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 42
- 239000011780 sodium chloride Substances 0.000 claims abstract description 21
- 239000001509 sodium citrate Substances 0.000 claims abstract description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 5
- 239000001632 sodium acetate Substances 0.000 claims abstract description 5
- 235000017281 sodium acetate Nutrition 0.000 claims abstract description 5
- 239000001103 potassium chloride Substances 0.000 claims abstract description 3
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 79
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 108010076282 Factor IX Proteins 0.000 claims description 21
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 20
- 229960004222 factor ix Drugs 0.000 claims description 20
- 108010074605 gamma-Globulins Proteins 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 108010054218 Factor VIII Proteins 0.000 claims description 6
- 102000001690 Factor VIII Human genes 0.000 claims description 6
- 229960000301 factor viii Drugs 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004411 Antithrombin III Human genes 0.000 claims description 4
- 108090000935 Antithrombin III Proteins 0.000 claims description 4
- 229960005348 antithrombin iii Drugs 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 abstract description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000011591 potassium Substances 0.000 abstract description 2
- 229910052700 potassium Inorganic materials 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 65
- 239000000243 solution Substances 0.000 description 60
- 238000002474 experimental method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 238000007873 sieving Methods 0.000 description 20
- 239000012460 protein solution Substances 0.000 description 19
- 238000010790 dilution Methods 0.000 description 18
- 239000012895 dilution Substances 0.000 description 18
- 238000012545 processing Methods 0.000 description 14
- 238000011026 diafiltration Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 11
- 230000035699 permeability Effects 0.000 description 11
- 241000125945 Protoparvovirus Species 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 239000013621 viresolve pro solution Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 239000004019 antithrombin Substances 0.000 description 5
- 210000004779 membrane envelope Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 238000005185 salting out Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 241000991587 Enterovirus C Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 150000002337 glycosamines Chemical class 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- -1 antithrombin III Proteins 0.000 description 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 229960004336 human antithrombin iii Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 108010048348 zinc hemoglobin Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Water Supply & Treatment (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Glass Compositions (AREA)
- Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9402254A SE502820C2 (sv) | 1994-06-23 | 1994-06-23 | Filtrering |
| SE9500724A SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Filtrering |
| PCT/SE1995/000777 WO1996000237A1 (en) | 1994-06-23 | 1995-06-22 | Filtration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965523D0 NO965523D0 (no) | 1996-12-20 |
| NO965523L NO965523L (no) | 1996-12-20 |
| NO320952B1 true NO320952B1 (no) | 2006-02-20 |
Family
ID=26662085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19965523A NO320952B1 (no) | 1994-06-23 | 1996-12-20 | Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US6486306B1 (de) |
| EP (1) | EP0796269B1 (de) |
| JP (1) | JP3676370B2 (de) |
| AT (1) | ATE212354T1 (de) |
| CA (1) | CA2192683C (de) |
| DE (2) | DE69525176T2 (de) |
| DK (1) | DK0796269T3 (de) |
| ES (1) | ES2105992T3 (de) |
| FI (1) | FI965145A0 (de) |
| GR (1) | GR970300038T1 (de) |
| MX (1) | MX9606639A (de) |
| NO (1) | NO320952B1 (de) |
| NZ (1) | NZ288789A (de) |
| PT (1) | PT796269E (de) |
| SE (1) | SE9500724D0 (de) |
| WO (1) | WO1996000237A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| EP0860444A1 (de) * | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Methode zur Entfernung von Viren aus Proteinlösungen |
| US6045588A (en) | 1997-04-29 | 2000-04-04 | Whirlpool Corporation | Non-aqueous washing apparatus and method |
| US6096872A (en) * | 1997-10-14 | 2000-08-01 | Ortho Diagnostic Systems, Inc. | Viral clearance process |
| FR2772381B1 (fr) * | 1997-12-15 | 2001-06-08 | Lab Francais Du Fractionnement | Procede de preparation par filtration d'une solution de facteur viii securisee viralement |
| US6861001B2 (en) * | 1999-12-02 | 2005-03-01 | The General Hospital Corporation | Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon |
| CN100507567C (zh) | 2002-05-23 | 2009-07-01 | 奥索临床诊断有限公司 | 朊病毒蛋白的去除 |
| CA2489123C (en) | 2002-06-14 | 2011-03-15 | Centocor, Inc. | Use of a clathrate modifier to promote passage of proteins during nanofiltration |
| JP2004099506A (ja) * | 2002-09-09 | 2004-04-02 | Mitsubishi Rayon Co Ltd | アミノ酸アミドの製造方法 |
| WO2004089402A1 (ja) * | 2003-04-09 | 2004-10-21 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | アルブミン製剤の製造方法 |
| JP4558652B2 (ja) * | 2003-06-20 | 2010-10-06 | マイクロビクス・バイオシステムズ・インコーポレイテツド | ウイルス生産の改善 |
| CN100398642C (zh) * | 2003-06-20 | 2008-07-02 | 迈克必斯生物系统公司 | 病毒生产的改进 |
| FR2861395B1 (fr) | 2003-10-23 | 2006-02-17 | Lab Francais Du Fractionnement | Facteur viii viralement securise a faible teneur en multimeres superieurs |
| US7695524B2 (en) | 2003-10-31 | 2010-04-13 | Whirlpool Corporation | Non-aqueous washing machine and methods |
| US7739891B2 (en) | 2003-10-31 | 2010-06-22 | Whirlpool Corporation | Fabric laundering apparatus adapted for using a select rinse fluid |
| EP2275432A1 (de) * | 2003-12-01 | 2011-01-19 | Novo Nordisk Health Care AG | Nanofiltration von Faktor VII Lösungen zur Entfernung von Viren |
| JP2007522814A (ja) | 2004-02-23 | 2007-08-16 | クルセル ホランド ベー ヴェー | ウイルスの精製方法 |
| FR2866890B1 (fr) * | 2004-02-27 | 2008-04-04 | Lab Francais Du Fractionnement | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
| EP1740757A1 (de) | 2004-04-29 | 2007-01-10 | Unilever N.V. | Chemisches reinigungsverfahren |
| US7141171B2 (en) * | 2004-05-21 | 2006-11-28 | Wisconsin Alumni Research Foundation | Membrane cascade-based separation |
| AU2005229674B2 (en) | 2004-11-18 | 2010-11-04 | Kedrion Melville Inc. | Low concentration solvent/detergent process of immuneglobulin with pre-treatment |
| AU2006233800B2 (en) | 2005-04-11 | 2011-07-07 | Crucell Holland B.V. | Virus purification using ultrafiltration |
| US7966684B2 (en) | 2005-05-23 | 2011-06-28 | Whirlpool Corporation | Methods and apparatus to accelerate the drying of aqueous working fluids |
| ES2775974T3 (es) * | 2006-06-26 | 2020-07-28 | Omrix Biopharmaceuticals Inc | Eliminación de virus por nanofiltración |
| CA2690673C (en) * | 2007-06-15 | 2013-04-23 | Amgen Inc. | Methods of treating cell culture media for use in a bioreactor |
| KR100870423B1 (ko) * | 2007-06-27 | 2008-11-26 | 주식회사 하이닉스반도체 | 반도체메모리소자 |
| US7989593B1 (en) | 2010-05-27 | 2011-08-02 | Bing Lou Wong | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US8048856B1 (en) | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US9359397B2 (en) | 2011-06-24 | 2016-06-07 | Asahi Kasei Medical Co., Ltd. | Method for manufacturing protein drug |
| US20130052232A1 (en) | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| US9294158B2 (en) | 2012-08-07 | 2016-03-22 | Broadcom Corporation | Broadcast audio service |
| KR102437202B1 (ko) | 2013-08-08 | 2022-08-29 | 시에스엘 리미티드 | 오염 제거 방법 |
| WO2018053384A1 (en) | 2016-09-19 | 2018-03-22 | Asgco Manufacturing, Inc. | Return idler trainer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870801A (en) | 1968-08-09 | 1975-03-11 | Lever Brothers Ltd | Fluid aqueous protein compositions and food products prepared therefrom |
| US3919044A (en) | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
| US3874999A (en) | 1973-10-31 | 1975-04-01 | American Cyanamid Co | Process for the purification of virus vaccine |
| CA1099576A (en) | 1978-03-23 | 1981-04-21 | Chester D. Myers | Improved process for isolation of proteins |
| US4473494A (en) | 1983-05-04 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Preparation of stroma-free, non-heme protein-free hemoglobin |
| US4684723A (en) * | 1985-09-11 | 1987-08-04 | Miles Laboratories, Inc. | Method of separating proteins from aqueous solutions |
| JPH0720986B2 (ja) | 1985-10-07 | 1995-03-08 | 日本ケミカルリサ−チ株式会社 | 生理活性物質の製造法 |
| AU605901B2 (en) * | 1987-09-11 | 1991-01-24 | Ares Trading S.A. | Purification process |
| RU1781355C (ru) * | 1990-04-23 | 1992-12-15 | В.П.Широбоков, Л.Я.Палиенко, А.И.Евтушенко, Л.А Коптюх, Ю.В.Загороднюк и К.Д Стеценко | Фильтрующий материал |
| US5017292A (en) | 1990-05-10 | 1991-05-21 | Millipore Corporation | Membrane, process and system for isolating virus from solution |
| US5076933A (en) | 1990-06-29 | 1991-12-31 | Coulter Corporation | Process and apparatus for removal of dna and viruses |
| US5221483A (en) * | 1990-06-29 | 1993-06-22 | Coulter Corporation | Process and apparatus for removal of DNA, viruses and endotoxins |
| SE9301582D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Purification of plasma proteins |
| SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
-
1995
- 1995-02-24 SE SE9500724A patent/SE9500724D0/xx unknown
- 1995-06-22 NZ NZ288789A patent/NZ288789A/en not_active IP Right Cessation
- 1995-06-22 ES ES95923651T patent/ES2105992T3/es not_active Expired - Lifetime
- 1995-06-22 MX MX9606639A patent/MX9606639A/es not_active IP Right Cessation
- 1995-06-22 US US08/750,664 patent/US6486306B1/en not_active Expired - Fee Related
- 1995-06-22 PT PT95923651T patent/PT796269E/pt unknown
- 1995-06-22 JP JP50306296A patent/JP3676370B2/ja not_active Expired - Fee Related
- 1995-06-22 AT AT95923651T patent/ATE212354T1/de not_active IP Right Cessation
- 1995-06-22 DE DE69525176T patent/DE69525176T2/de not_active Revoked
- 1995-06-22 EP EP95923651A patent/EP0796269B1/de not_active Revoked
- 1995-06-22 CA CA002192683A patent/CA2192683C/en not_active Expired - Fee Related
- 1995-06-22 WO PCT/SE1995/000777 patent/WO1996000237A1/en active IP Right Grant
- 1995-06-22 DE DE0796269T patent/DE796269T1/de active Pending
- 1995-06-22 DK DK95923651T patent/DK0796269T3/da active
-
1996
- 1996-12-20 FI FI965145A patent/FI965145A0/fi not_active Application Discontinuation
- 1996-12-20 NO NO19965523A patent/NO320952B1/no not_active IP Right Cessation
-
1997
- 1997-11-28 GR GR970300038T patent/GR970300038T1/el unknown
-
2000
- 2000-02-23 US US09/511,953 patent/US6399357B1/en not_active Expired - Fee Related
-
2002
- 2002-11-26 US US10/304,902 patent/US20030191292A1/en not_active Abandoned
-
2005
- 2005-02-23 US US11/064,770 patent/US20050203285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69525176D1 (de) | 2002-03-14 |
| ES2105992T1 (es) | 1997-11-01 |
| NO965523D0 (no) | 1996-12-20 |
| EP0796269A1 (de) | 1997-09-24 |
| ES2105992T3 (es) | 2002-09-16 |
| FI965145A (fi) | 1996-12-20 |
| DE796269T1 (de) | 1998-01-02 |
| ES2105992T2 (es) | 1997-11-01 |
| PT796269E (pt) | 2002-06-28 |
| US6399357B1 (en) | 2002-06-04 |
| CA2192683A1 (en) | 1996-01-04 |
| US20050203285A1 (en) | 2005-09-15 |
| MX9606639A (es) | 1997-03-29 |
| US6486306B1 (en) | 2002-11-26 |
| JPH10502074A (ja) | 1998-02-24 |
| FI965145A0 (fi) | 1996-12-20 |
| CA2192683C (en) | 2005-07-05 |
| WO1996000237A1 (en) | 1996-01-04 |
| DE69525176T2 (de) | 2002-06-27 |
| ATE212354T1 (de) | 2002-02-15 |
| NO965523L (no) | 1996-12-20 |
| SE9500724D0 (sv) | 1995-02-24 |
| GR970300038T1 (en) | 1997-11-28 |
| AU682274B2 (en) | 1997-09-25 |
| AU2813295A (en) | 1996-01-19 |
| US20030191292A1 (en) | 2003-10-09 |
| JP3676370B2 (ja) | 2005-07-27 |
| EP0796269B1 (de) | 2002-01-23 |
| NZ288789A (en) | 1997-12-19 |
| DK0796269T3 (da) | 2002-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320952B1 (no) | Fremgangsmate for virusfiltrering av en losning inneholdende minst ett makromolekyl | |
| JP3094167B2 (ja) | 免疫血清グロブリンの精製方法 | |
| US4877866A (en) | Method of producing a virus safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation | |
| CA2254871C (en) | Purification of biologically active peptides from milk | |
| RU2000113224A (ru) | Способ продуцирования в высокой степени вирусобезопасных компонентов для получения фибринового клея из пула плазмы человека | |
| AU709584B2 (en) | Industrial production process for a vaccine against Japanese encephalitis, and vaccine obtained | |
| NO863424L (no) | Fremgangsmaate for rensing av et interferon. | |
| EP0176926B1 (de) | Verfahren zur Herstellung eines hochgereinigten Antihämophilfaktor-Konzentrats | |
| NO323460B1 (no) | Fremgangsmate til fremstilling i stor skala av en lagringsstabil trombinsammensetning med terapeutisk kvalitet som hovedsakelig er fri for virus | |
| US4199450A (en) | Process of separating from an aqueous medium a protein or a morphologically organized unit by liquid exclusion chromatography | |
| IL177286A (en) | Albumin purification method comprising a nanofiltration step and solution and composition for therapeutic use containing same | |
| JP4312381B2 (ja) | 濾過によるウイルス的に安全な因子ｖｉｉｉ溶液の調製方法 | |
| US8293242B2 (en) | Ultra-high yield of alpha-1-anti-trypsin | |
| CN110678481B (zh) | 用于纯化白蛋白的方法 | |
| TWI593702B (zh) | 純化由細胞培養而來的ａｌｐｈａ蛋白酶抑制劑 | |
| AU682274C (en) | Filtration | |
| US10800820B2 (en) | Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents | |
| JPH08787B2 (ja) | ガンマグロブリン含有組成物の製造法 | |
| RU2066188C1 (ru) | Способ получения человеческого лейкоцитарного интерферона | |
| EP0126789B1 (de) | Antihaemophilisches Faktorkonzentrat und Verfahren zur Herstellung | |
| JP2678193B2 (ja) | ヒト血漿由来血液凝固第ｘ▲ｉｉｉ▼因子の製造方法 | |
| SE502820C2 (sv) | Filtrering | |
| JP2000212097A (ja) | 伝達性海綿状脳症病原因子を除去する方法 | |
| NO149610B (no) | Fremgangsmaate for rensing av den antihemofile faktor, faktor viii | |
| DK146098B (da) | Fremgangsmaade til rensning af faktor viii (antihemofil faktor) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |